Kommuniké från årsstämma i Acarix AB
Årsstämman 2024 i Acarix AB ("Acarix" eller "Bolaget") hölls idag den 14 maj 2024 varvid aktieägarna fattade f&oum...
Acarix AB (publ) publishes Interim Report, January – March 2024
Setting the stage for a strong 2024 and beyondOne of the most notable achievements this quarter has been the successful implementation ...
Proposal by the nomination committee prior to the 2024 annual general meeting of Acarix AB (publ)
The Nomination Committee of Acarix consists of Jan Poulsen (Chairman) representing Life Science Invest Fund 1 among others, Anton Rehns...
Acarix AB’s Annual Report 2023
Acarix, a leader in advanced acoustic-based cardiac diagnostics, today announces that the Annual Report for 2023 is available as a pdf ...
Acarix AB’s Årsredovisning 2023
Acarix, ledande inom avancerad akustikbaserad hjärtdiagnostik, meddelar idag att årsredovisning för 2023 finns tillg&au...
KALLELSE TILL ÅRSSTÄMMA I ACARIX AB
Aktieägarna i Acarix AB, org.nr 559009-0667 ("Bolaget"), kallas härmed till årsstämma tisdagen den 14 maj 2024 kl....
NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB
The shareholders of Acarix AB, reg. no. 559009-0667 (the "Company"), are hereby invited to the annual general meeting on Tuesday 14 May...
Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review
Acarix, a leader in advanced acoustic- and algorithm-based cardiac diagnostics, announces the adoption of a new innovative usage-based ...
Acarix antar ny tillväxtfokuserad affärsmodell och ger en uppdatering av strategiska och finansiella mål
Acarix, ledande aktör inom akustik- och algoritmbaserad hjärtdiagnostik, tillkännager idag införandet av en ny inno...
Acarix announces the outcome of the exercise of warrants of series 2024:U1 (TO2)
The Board of directors of Acarix AB ("Acarix" or the "Company") today announces the outcome of the exercise period for warrants of seri...
Acarix offentliggör utfall av utnyttjande av teckningsoptioner av serie 2024:U1 (TO2)
Styrelsen för Acarix AB (”Acarix” eller ”Bolaget”) offentliggör idag utfallet av utnyttjandeperioden ...
The exercise period for Acarix warrants of series 2024:U1 (TO2) begins today
The exercise period for the warrants of series 2024:U1 (TO2) (the "Warrants") issued in connection with Acarix AB ("Acarix" or the "Com...